Challenges faced in the treatment of acute lymphoblastic leukemia in adolescents and young adults

Figures & data

Table 1 Outcomes for adolescent and young adult patients treated on pediatric-based versus adult-based clinical trials

Country	Clinical trials (pediatric/adult)	Age range (years)	Pediatric regimen	Adult regimen
USA^Citation40	CCG^p/CALGB^a	16–21	EFS: 63% at 7 yr	EFS: 34% at 7 yr
USA^Citation54	CCG100 series^p	16–21	EFS: 72% at 5 yr
France^Citation59	FRALLE93^p/LALA94^a	15–20	DFS: 68% at 6 yr	DFS: 32% at 4 yr
France^Citation69	GRAALL 2003^a	15–60		EFS: 55% at 4 yr
Finland^Citation62	NOPHO^p/FLGN^a	10–25	EFS: 67% at 5 yr	EFS: 60% at 5 yr
Great Britain^Citation70	ALL97^p/UKALLXII^a	15–17	EFS: 65% at 5 yr	EFS: 49% at 5 yr
UK^Citation19	MRC UKALLX,X^a	15–20		DFS: 35% at 5 yr
The Netherlands^Citation61	DCOG^p/HVON^a	15–18	EFS: 69% at 5 yr	EFS: 34% at 5 yr

Notes: ^pPediatric-based oncology trial;

a adult-based oncology trial.

Abbreviations: EFS, event-free survival; DFS, disease-free survival; yr, years.

Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008; 112(5):1646–1654.

 PubMed Web of Science ®Google Scholar

Nachman J, Sather HN, Buckley JD, et al. Young adults 16–21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment. Cancer. 1993;71(Suppl 10):3377–3385.

 PubMed Web of Science ®Google Scholar

Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21(5):774–780.

 PubMed Web of Science ®Google Scholar

Gupta V, Richards S, Rowe J. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood. 2013;121(2):339–350.

 PubMed Web of Science ®Google Scholar

Usvasalo A, Raty R, Knuutila S, et al. Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica. 2008; 93(8):1161–1168.

 PubMed Web of Science ®Google Scholar

Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111(4):1827–1833.

 PubMed Web of Science ®Google Scholar

Ramanujachar R, Richards S, Hann I, Webb D. Adolescents with acute lymphoblastic leukaemia: emerging from the shadow of paediatric and adult treatment protocols. Pediatr Blood Cancer. 2006;47(6):748–756.

 PubMed Web of Science ®Google Scholar

de Bont JM, Holt B, Dekker AW, van der Does-van den Berg A, Sonneveld P, Pieters R. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 2004;18(12):2032–2035.

 PubMed Web of Science ®Google Scholar